Health-related quality of life in transplant ineligible newly diagnosed multiple myeloma patients treated with either thalidomide or lenalidomide-based regimen until progression : A prospective, open-label, multicenter, randomized, phase 3 study

↓ Direkt till sidans innehåll
↓ Direkt till sidans sekundära innehåll (sidomenyn)

Search: onr:"swepub:oai:lup.lub.lu.se:78f8c9e1-3b92-4677-a542-20c86d4eec24" > Health-related qual...

1 of 1
Previous record
Next record
To hitlist

Health-related quality of life in transplant ineligible newly diagnosed multiple myeloma patients treated with either thalidomide or lenalidomide-based regimen until progression : A prospective, open-label, multicenter, randomized, phase 3 study

Nielsen, Lene Kongsgaard (author): Odense University Hospital

Stege, Claudia (author): Vrije Universiteit Amsterdam

Lissenberg-Witte, Birgit (author): Vrije Universiteit Amsterdam

Der Holt, Bronno Van (author): Erasmus University Medical Center

Mellqvist, Ulf Henrik (author): Sahlgrenska University Hospital

Salomo, Morten (author): Copenhagen University Hospital

Bos, Gerard (author): Yukioka Hospital

Levin, Mark David (author)

Visser-Wisselaar, Heleen (author): Erasmus University Medical Center

Hansson, Markus (author): Lund University,Lunds universitet,Avdelningen för hematologi och transfusionsmedicin,Institutionen för laboratoriemedicin,Medicinska fakulteten,Myelomgruppen,Forskargrupper vid Lunds universitet,WCMM- Wallenberg center för molekylär medicinsk forskning,LUCC: Lunds universitets cancercentrum,Övriga starka forskningsmiljöer,Division of Hematology and Transfusion Medicine,Department of Laboratory Medicine,Faculty of Medicine,Myeloma research group,Lund University Research Groups,WCMM-Wallenberg Centre for Molecular Medicine,LUCC: Lund University Cancer Centre,Other Strong Research Environments,Skåne University Hospital

Der Velden, Annette Van (author): Martini Hospital, Groningen

Deenik, Wendy (author)

Coenen, Juleon (author): Maastricht University Medical Centre

Hinge, Maja (author): Vejle Hospital

Klein, Saskia (author): Meander Medical Center

Tanis, Bea (author)

Szatkowski, Damian (author)

Brouwer, Rolf (author): Reinier de Graaf Hospital - SSDZ

Westerman, Matthijs (author)

Leys, Rineke (author)

Sinnige, Harm (author): Jeroen Bosch Hospital

Haukås, Einar (author): Stavanger University Hospital

Der Hem, Klaas Van (author)

Durian, Marc (author)

Gimsing, Peter (author): Copenhagen University Hospital

De Donk, Niels Van (author): Vrije Universiteit Amsterdam

Sonneveld, Pieter (author): Erasmus University Medical Center

Waage, Anders (author): St. Olav’s University Hospital

Abildgaard, Niels (author): Odense University Hospital

Zweegman, Sonja (author): Vrije Universiteit Amsterdam

show less...

(creator_code:org_t)

2019-09-12
2020
English 10 s.
In: Haematologica. - : Ferrata Storti Foundation (Haematologica). - 0390-6078 .- 1592-8721. ; 105:6, s. 1650-1659

Related links:: http://dx.doi.org/10... (free); show more...; https://haematologic...; https://lup.lub.lu.s...; https://doi.org/10.3...; show less...

Journal article (peer-reviewed)

Abstract Subject headings

Data on the impact of long term treatment with immunomodulatory drugs (IMiD) on health-related quality of life (HRQoL) is limited. The HOVON-87/NMSG18 study was a randomized, phase 3 study in newly diagnosed transplant ineligible patients with multiple myeloma, comparing melphalan-prednisolone in combination with thalidomide or lenalidomide, followed by maintenance therapy until progression (MPT-T or MPR-R). The EORTC QLQ-C30 and MY20 questionnaires were completed at baseline, after three and nine induction cycles and six and 12 months of maintenance therapy. Linear mixed models and minimal important differences were used for evaluation. 596 patients participated in HRQoL reporting. Patients reported clinically relevant improvement in global quality of life (QoL), future perspective and role and emotional functioning, and less fatigue and pain in both arms. The latter being of large effect size. In general, improvement occurred after 6-12 months of maintenance only and was independent of the World Health Organisation performance at baseline. Patients treated with MPR-R reported clinically relevant worsening of diarrhea, and patients treated with MPT-T reported a higher incidence of neuropathy. Patients who remained on lenalidomide maintenance therapy for at least three months reported clinically meaningful improvement in global QoL and role functioning at six months, remaining stable thereafter. There were no clinically meaningful deteriorations, but patients on thalidomide reported clinically relevant worsening in neuropathy. In general, HRQoL improves both during induction and maintenance therapy with immunomodulatory drugs. The side effect profile of treatment did not negatively affect global QoL, but it was, however, clinically relevant for the patients.

Find in a library

Haematologica (Search for host publication in LIBRIS)

To the university's database

1 of 1
Previous record
Next record
To hitlist

Find more in SwePub

About the subject

MEDICAL AND HEALTH SCIENCES: MEDICAL AND HEAL ...; and Clinical Medicin ...; and Hematology

Articles in the publication: Haematologica

By the university: Lund University

Search outside SwePub

Extend your search to:: Google; Google Book Search; Google Scholar

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

LIBRIS.kb.se

Health-related quality of life in transplant ineligible newly diagnosed multiple myeloma patients treated with either thalidomide or lenalidomide-based regimen until progression : A prospective, open-label, multicenter, randomized, phase 3 study

Subject headings

Publication and Content Type

Find in a library

To the university's database

Find more in SwePub

Search outside SwePub